Published in Sci Rep on July 19, 2016
The Potential for Circulating Tumor Cells in Pancreatic Cancer Management. Front Physiol (2017) 0.76
Prognostic value of circulating tumor cells in the peripheral blood of patients with esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science (2013) 10.87
Circulating tumor cells: approaches to isolation and characterization. J Cell Biol (2011) 6.54
Continuous particle separation through deterministic lateral displacement. Science (2004) 5.60
Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol (2000) 5.26
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. J Clin Oncol (2011) 4.72
Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell (2014) 4.44
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res (2009) 3.76
Cancer micrometastases. Nat Rev Clin Oncol (2009) 3.69
Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev (2013) 3.63
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A (2009) 3.19
EpCAM (CD326) finding its role in cancer. Br J Cancer (2007) 2.98
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol (2014) 2.73
Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. J Clin Oncol (2006) 2.58
Isolation and retrieval of circulating tumor cells using centrifugal forces. Sci Rep (2013) 2.30
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc (2014) 1.80
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer (2011) 1.50
Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal of a definition and a consensus protocol. J Thromb Haemost (2006) 1.49
CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A (2011) 1.47
Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer (2008) 1.34
Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res (2014) 1.34
Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg (2008) 1.33
Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res (2013) 1.29
Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer (2013) 1.20
Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med (2011) 1.15
Circulating tumor cell enumeration with a combination of epithelial cell adhesion molecule- and cell-surface vimentin-based methods for monitoring breast cancer therapeutic response. Clin Chem (2014) 1.12
A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost (2012) 1.08
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. Clin Cancer Res (2015) 1.03
The detection of EpCAM(+) and EpCAM(-) circulating tumor cells. Sci Rep (2015) 1.02
Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer. Ann Oncol (2012) 1.02
Cell adhesion and polarity during immune interactions. Immunol Rev (2002) 0.95
Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer (2012) 0.91
Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System. PLoS One (2015) 0.90
Circulating Tumor Cells: A Review of Non-EpCAM-Based Approaches for Cell Enrichment and Isolation. Clin Chem (2016) 0.88
Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology (2015) 0.88
Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg (2016) 0.87
Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometry. Cancer (2015) 0.86
Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. Br J Cancer (2015) 0.84
Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma. Clin Chem (2016) 0.80